Pharmaceutical Executive-10-01-2008

Pharmaceutical Executive
Features

October 01, 2008

Manufacturers overpay PBMs millions of dollars each year in rebates overpayments. Here's how to stop the leakage.

Pharmaceutical Executive
Columns

October 01, 2008

It's management makeover time-and micromanaging is so last year.

Pharmaceutical Executive
Features

October 01, 2008

Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success?

Pharmaceutical Executive
Leadership

October 01, 2008

Try this one on for size: Multi-tasking isn't the path to greatness

Pharmaceutical Executive
Features

October 01, 2008

Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.

Pharmaceutical Executive
Global Report

October 01, 2008

Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems

Pharmaceutical Executive
Columns

October 01, 2008

What's the buzz all about? Word of mouth is more effective than we think.

Pharmaceutical Executive
Features

October 01, 2008

Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug.

Back Page
Pharmaceutical Executive

October 01, 2008

A head-to-head comparison of the Drug Vote '08

Pharmaceutical Executive
Columns

October 01, 2008

Web analystics is helping a new generation of pharma web sites get engaged.

Pharmaceutical Executive
From the Editor

October 01, 2008

A vision of pharma's next business model is starting to emerge. But how do we get from here to there?

Pharmaceutical Executive
Washington Report

October 01, 2008

Congressional leaders ready campaign to curb Medicare drug plans.

Pharmaceutical Executive
Columns

October 01, 2008

Enter the Maturity Matrix: the future of KOL management organization.

Thought Leader
Pharmaceutical Executive

October 01, 2008

Cubist Pharmaceuticals CEO Michael Bonney has given the company a successful start-and is now predicting the future of drug resistance.

Pharmaceutical Executive
Features

October 01, 2008

Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in effciency.